Team

Lisa Hutchinson, PhD

Lisa gained her first-class honours degree in biochemistry from University College London and her PhD at the Institute of Cancer Research. Her career spans more than 17 years in science and clinical publishing, with her first appointment as Assistant Editor, then soon promoted to Journal Editor of Breast Cancer Research. Lisa was the Founding Chief Editor of Nature Reviews Clinical Oncology, which she launched in 2004. As Chief Editor for 14 years, she has written numerous editorials and more than 300 research highlight publications, and has forged multiple collaborations within the oncology community. She was a member of the non-profit DFMO Task Force (2016) that has initiated a maintenance phase II trial for patients with high-risk neuroblastoma. Lisa has done freelance writing for the clinical oncology publication Cancer World and overseen peer review for the BMJ Open and more recently helped with various clinical trial research projects on Consilium Scientific.

CHEEGEE SEE, PHD

25+ years of industry experience in big pharma (GSK, Roche) and SME biotechs (Proteome Sciences, Global Gene Corp, Trajecture) with an excellent working network of C-level decision-makers. Deep oncology clinical trial expertise – Clinical biomarker and experimental medicine leader for Roche’s Herceptin Phase 3 registration trial (ToGA study) for gastric cancer, 2006-2011. Deep oncology discovery research and drug development – Head of Translational Medicine at Global Gene Corp developing novel drug for prostate cancer, 2017. Deep expertise in Precision Medicines, companion diagnostics and biomarker technologies in multiple therapeutic areas – Global Head of Personalized Medicine at Proteome Sciences, 2013-2016. Published book chapter, November 2019 – ‘Clinical Strategies for Developing Next-Generation Cancer Precision Medicines’. Visiting professor at the University of Surrey, teaching MSc module in ‘Pharmaceutical Medicine’, 2015. CheeGee is a visionary strategist who is passionate about translating medical knowledge into transformative treatment options and creating strong and sustainable commercial value.

NATHAN NAGEL 

Mr Nathan Nagel has led a global oncology network for 15 years with over 45,000 members. Nathan is an entrepreneur with 23 years’ experience on the commercial side of healthcare with 13 years’ experience of being an executive director. Nathan has deep connections and understanding of the markets of the UK, EU, USA and Middle East. He is currently the CEO of the Fratrem Group Ltd and P/T commercial director of 3 other medical companies. His past executive experience includes CEO at Gamlen Tableting Ltd (Pharmaceuticals), Managing Director of Sanyal Bio LLC (Liver disease), CEO of Neuro-Bio Ltd (Neuroscience), CEO of Oncology Pharma Ltd (Market research company), and Managing partner of LifeScience Ventures Ltd (Healthcare Venture Capital). Prior to leading companies Nathan worked in commercial roles for Bayer Diagnostics and Takeda Pharmaceuticals, where he started his career.